Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25298659 | 1.00 | DPP4 (0.32) | DPP4DPP7OPRM1OPRD1OPRK1 | |
| SCHEMBL25298817 | 1.00 | DPP4 (0.32) | DPP4DPP7OPRM1OPRD1OPRK1 | |
| SCHEMBL23826817 | 0.80 | DPP4 (0.32) | DPP4DPP7LTA4HCYP1A2CYP2C9 | |
| SCHEMBL23826856 | 0.80 | DPP4 (0.32) | DPP4DPP7LTA4HCYP1A2CYP2C9 | |
| SCHEMBL23825705 | 0.78 | DPP4 (0.37) | DPP4DPP7LTA4HCYP1A2CYP2C9 | |
| SCHEMBL23825703 | 0.78 | DPP4 (0.37) | DPP4DPP7LTA4HCYP1A2CYP2C9 | |
| SCHEMBL18446307 | 0.76 | — | — | |
| SCHEMBL18423086 | 0.75 | USP2 (0.47) | DPP4OPRD1OPRK1 | |
| SCHEMBL25847258 | 0.75 | USP2 (0.47) | DPP4OPRD1OPRK1 | |
| SCHEMBL25847257 | 0.75 | USP2 (0.47) | DPP4OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2023133543-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-3328849-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | Pfizer Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| CN-107849017-A | 1,1, 1-trifluoro-3-hydroxypropan-2-ylcarbamate derivatives and 1,1, 1-trifluoro-4-hydroxybutyl-2-ylcarbamate derivatives as MAG L inhibitors | 辉瑞公司 | 2018-03-27 | — | — | CN | disclosed |
| WO-2017021805-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2017-02-09 | — | — | WO | disclosed |